Senzime AB
Company Profile
Business description
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
Contact
Verkstadsgatan 8, hus 1
Uppsala753 23
SWET: +46 18515640
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.90 | 58.60 | -0.65% |
| CAC 40 | 8,230.77 | 80.35 | 0.99% |
| DAX 40 | 24,942.05 | 146.11 | 0.59% |
| Dow JONES (US) | 51,302.30 | 615.23 | 1.21% |
| FTSE 100 | 10,327.50 | 4.80 | -0.05% |
| HKSE | 25,253.40 | 379.81 | -1.48% |
| NASDAQ | 26,623.32 | 230.65 | -0.86% |
| Nikkei 225 | 67,470.69 | 931.45 | -1.36% |
| NZX 50 Index | 13,101.61 | 13.47 | -0.10% |
| S&P 500 | 7,539.90 | 13.78 | -0.18% |
| S&P/ASX 200 | 8,686.10 | 59.50 | -0.68% |
| SSE Composite Index | 4,057.78 | 26.19 | -0.64% |